OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
CN Stock MarketDetailed Quotes
600354 Gansu Dunhuang Seed Group
- 5.58
- +0.08+1.45%
Not Open Apr 1 15:00 CST
2.95BMarket Cap58.74P/E (TTM)
5.62High5.51Low84.80KlotVolume5.52Open5.50Pre Close47.32MTurnover1.61%Turnover Ratio58.74P/E (Static)527.80MShares7.0152wk High4.52P/B2.95BFloat Cap4.3652wk Low6.05Limit Up527.80MShs Float18.02Historical High4.95Limit Down2.00%Amplitude1.04Historical Low--Dividend TTM5.58Avg Price42.11KlotAsk--Div YieldTTM100Lot Size42.06KlotBid
Gansu Dunhuang Seed Group Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -0.16%1.16B | 31.39%690.37M | 27.99%590.26M | 26.20%443.21M | 15.24%1.16B | 30.36%525.44M | 49.04%461.18M | 70.27%351.21M | 8.95%1B | -8.59%403.06M |
| Operating revenue | -0.16%1.16B | 31.39%690.37M | 27.99%590.26M | 26.20%443.21M | 15.24%1.16B | 30.36%525.44M | 49.04%461.18M | 70.27%351.21M | 8.95%1B | -8.59%403.06M |
| Other operating revenue | -52.75%34.22M | ---- | -59.25%13.76M | ---- | 148.79%72.42M | ---- | 280.08%33.75M | ---- | 76.86%29.11M | ---- |
| Total operating cost | -3.77%991.07M | 21.87%596.49M | 22.82%471.72M | 19.99%316.83M | 7.94%1.03B | 14.42%489.46M | 30.40%384.07M | 49.80%264.05M | 2.95%954.15M | -10.49%427.77M |
| Operating cost | -6.24%783.78M | 28.13%454.29M | 24.22%374.12M | 21.92%274.93M | 10.09%835.99M | 20.13%354.55M | 43.09%301.18M | 66.87%225.5M | 4.82%759.38M | -12.36%295.14M |
| Operating tax surcharges | -17.64%7.91M | -8.91%4.16M | -4.60%3.69M | -22.17%659.83K | 31.98%9.61M | 24.61%4.56M | 21.85%3.87M | 68.48%847.74K | 4.82%7.28M | 12.03%3.66M |
| Operating expense | 19.04%54.84M | 14.66%35.04M | 31.97%23.6M | 12.06%8.57M | 0.81%46.07M | -8.49%30.56M | -12.16%17.88M | -27.62%7.65M | -16.08%45.7M | -17.11%33.4M |
| Administration expense | 5.18%118.89M | 3.55%85.58M | 18.16%59.36M | 15.12%28.19M | 3.34%113.03M | 8.83%82.65M | 4.58%50.23M | 5.13%24.49M | 5.99%109.37M | 2.54%75.94M |
| Financial expense | -38.42%5.33M | -29.33%4.98M | -35.70%3.19M | -53.06%1.67M | -32.32%8.65M | -23.50%7.05M | -28.51%4.97M | -23.61%3.56M | -44.15%12.78M | -38.79%9.21M |
| -Interest expense (Financial expense) | -18.24%14.97M | -21.55%9.85M | -26.79%6.95M | -26.32%3.58M | -16.12%18.31M | -12.78%12.55M | -5.95%9.5M | -4.10%4.86M | -17.49%21.83M | -18.94%14.39M |
| -Interest Income (Financial expense) | 10.79%-8.01M | 12.12%-5.69M | 21.57%-3.89M | 19.27%-2.18M | -35.56%-8.98M | -51.03%-6.48M | -69.20%-4.96M | -104.57%-2.71M | -44.74%-6.62M | -41.28%-4.29M |
| Research and development | 22.87%20.31M | 23.31%12.43M | 30.71%7.76M | 40.31%2.8M | -15.82%16.53M | -3.19%10.08M | 7.35%5.94M | -5.15%2M | 32.47%19.64M | 23.82%10.41M |
| Credit Impairment Loss | -85.81%-5.59M | -22.49%-4.64M | -6.05%-4.43M | 2.99%-5.93M | 13.30%-3.01M | -1.49%-3.79M | 0.97%-4.18M | -54.69%-6.12M | 38.10%-3.47M | 7.16%-3.73M |
| Asset Impairment Loss | -120.15%-13.02M | ---- | ---- | ---- | -23.39%-5.92M | ---- | ---- | ---- | -156.34%-4.79M | 118.58%242.89K |
| Other net revenue | -105.28%-570.43K | -21.38%6.96M | 236.36%4.34M | 2.38%-2.71M | 79.41%10.81M | 87.14%8.85M | 8.31%1.29M | -548.37%-2.78M | -80.78%6.02M | -70.88%4.73M |
| Fair value change income | ---- | -61.82%40.32K | ---- | 366.04%63.29K | --150.29K | --105.6K | ---65.65K | --13.58K | ---- | ---- |
| Invest income | -67.59%527.6K | -68.44%544.68K | -52.48%393.12K | -71.80%123.22K | 645.39%1.63M | 344.16%1.73M | --827.27K | --437.01K | -289.76%-298.5K | 147.02%388.59K |
| Asset deal income | -81.26%1.07M | -75.21%1.1M | 364.73%1.08M | ---- | 171.02%5.71M | 188.93%4.42M | -72.62%232.44K | 2,942.52%193.67K | -87.05%2.11M | -88.48%1.53M |
| Other revenue | 34.37%16.45M | 55.29%9.92M | 63.11%7.3M | 12.66%3.04M | -1.92%12.24M | 1.37%6.39M | -1.91%4.47M | 9.81%2.7M | 3.97%12.48M | -22.45%6.3M |
| Operating profit | 18.46%164.29M | 124.93%100.84M | 56.74%122.88M | 46.55%123.67M | 145.22%138.69M | 324.44%44.83M | 386.90%78.4M | 185.38%84.39M | 111.93%56.56M | 3.53%-19.98M |
| Add:Non operating Income | 32.63%9.98M | 286.27%9.11M | 128.43%5.02M | 524.66%2.46M | -8.77%7.53M | -36.85%2.36M | -25.33%2.2M | -72.27%394.12K | -24.62%8.25M | -60.04%3.73M |
| Less:Non operating expense | -85.00%2.61M | -60.29%443.66K | -56.76%286.87K | -90.34%38.78K | 103.27%17.37M | -13.88%1.12M | -44.22%663.48K | 154.61%401.29K | 455.46%8.54M | 370.23%1.3M |
| Total profit | 33.23%171.67M | 137.68%109.51M | 59.65%127.61M | 49.43%126.09M | 129.01%128.85M | 362.70%46.07M | 347.70%79.93M | 173.66%84.38M | 55.88%56.26M | -50.71%-17.54M |
| Less:Income tax cost | 75.08%54.66M | 55.78%39.61M | 41.62%40.69M | 42.92%35.66M | 525.43%31.22M | 2,548.76%25.43M | 6,799.54%28.73M | 17,727.93%24.95M | -23.38%-7.34M | 94.83%959.99K |
| Net profit | 19.85%117.01M | 238.55%69.9M | 69.77%86.92M | 52.17%90.43M | 53.49%97.62M | 211.61%20.65M | 193.61%51.2M | 93.61%59.43M | 51.28%63.6M | -52.50%-18.5M |
| Net profit from continuing operation | 19.85%117.01M | 238.55%69.9M | 69.77%86.92M | 52.17%90.43M | 53.49%97.62M | 211.61%20.65M | 193.61%51.2M | 93.61%59.43M | 51.28%63.6M | -52.50%-18.5M |
| Less:Minority Profit | 18.12%67.13M | 51.86%51.91M | 44.02%55.52M | 46.66%50.96M | 30.37%56.83M | 111.02%34.19M | 61.92%38.55M | 53.12%34.75M | 32.14%43.59M | 56.57%16.2M |
| Net profit of parent company owners | 22.26%49.88M | 232.84%17.98M | 148.24%31.4M | 59.92%39.47M | 103.88%40.8M | 60.98%-13.54M | 298.57%12.65M | 208.42%24.68M | 121.07%20.01M | -54.37%-34.7M |
| Earning per share | ||||||||||
| Basic earning per share | 22.25%0.0945 | 232.68%0.0341 | 147.92%0.0595 | 59.83%0.0748 | 103.96%0.0773 | 60.88%-0.0257 | 298.35%0.024 | 207.89%0.0468 | 120.35%0.0379 | -54.23%-0.0657 |
| Diluted earning per share | 22.25%0.0945 | 232.68%0.0341 | 147.92%0.0595 | 59.83%0.0748 | 103.96%0.0773 | 60.88%-0.0257 | 298.35%0.024 | 207.89%0.0468 | 120.35%0.0379 | -54.23%-0.0657 |
| Other composite income | 777.44%3.49M | 667.6K | -161.29%-515.7K | 147.90%841.45K | ||||||
| Other composite income of parent company owners | 777.44%3.49M | --667.6K | ---- | ---- | -161.29%-515.7K | ---- | ---- | ---- | 147.90%841.45K | ---- |
| Total composite income | 24.09%120.5M | 241.78%70.57M | 69.77%86.92M | 52.17%90.43M | 50.69%97.11M | 211.61%20.65M | 193.61%51.2M | 93.61%59.43M | 59.97%64.44M | -52.50%-18.5M |
| Total composite income of parent company owners | 32.50%53.37M | 237.77%18.65M | 148.24%31.4M | 59.92%39.47M | 93.18%40.28M | 60.98%-13.54M | 298.57%12.65M | 208.42%24.68M | 185.85%20.85M | -54.37%-34.7M |
| Total composite income of minority owners | 18.12%67.13M | 51.86%51.91M | 44.02%55.52M | 46.66%50.96M | 30.37%56.83M | 111.02%34.19M | 61.92%38.55M | 53.12%34.75M | 32.14%43.59M | 56.57%16.2M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.